Shenzhen Magicrna Biotechnology Co., Ltd

This early study tested a new treatment called HN2301 in 9 adults with refractory myasthenia gravis, a severe muscle weakness condition. The main goal was to check safety and side effects. The trial was terminated early, so results are limited.